semaglutide and liver disease Active ingredient in weight loss drug Wegovy may help treat type of fatty disease: Study Semaglutide Reduces Severity of Common

Tirzepatide is an approved, extensively studied dual agonist with a proven safety record, commercial availability, and the most comprehensive Phase 3 dataset in the GLP-1 class

However, information about the GLP-1 pulmonary aspiration risk was not included on the warning labels for Ozempic, Wegovy and other widely used drugs in this class, until now

Category 2 is reserved for substances flagged as higher safety risk

Investigations focus on how multi-receptor peptide agonists may influence physiological systems involved in energy balance and metabolic activity

Two patients can take the same medication and have very different outcomes